Recombinant Proteins iso9001 ISO13485
搜索
 > 【Serpin A1】重组蛋白信息

Serpin A1信息

英文名称:Alpha-1-antiproteinase
中文名称:α1-抗胰蛋白酶
靶点别称:PRO0684,SPAAT,SERPINA1,Alpha-1-antiproteinase,PRO2209,Serpin Family A Member 1,alpha 1-Antitrypsin,Protease Inhibitor 1 (Anti-Elastase), Alpha-1-Antitrypsin,Alpha-1 Protease Inhibitor,Serpin A1,AAT,PI,Serpin Peptidase Inhibitor Clade A (Alpha-1antiprotein
上市药物数量:1
临床药物数量:5
最高研发阶段:批准上市

Serpin A1产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
SE1-H5226
Human
Human Serpin A1 Protein, His Tag
 
评论(0)
 

Serpin A1 分子别名

SerpinA1,PI,A1A,AAT,PI1,A1AT,MGC9222,PRO2275,MGC23330,alpha1AT,SPAAT

Serpin A1 分子背景

Serpin A1 is also known as Alpha-1-antitrypsin (A1AT), serum trypsin inhibitor, alpha-1 proteinase inhibitor (A1PI), AAT, which belongs to the serpin family. Most serpins inactivate enzymes by binding to them covalently, requiring very high levels to perform their function. Like all serine protease inhibitors, A1AT has a characteristic secondary structure of beta sheets and alpha helices. Serpin A1 / A1AT is inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form of SerpinA1 inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin. Serpin A1 / A1AT protects tissues from enzymes of inflammatory cells, especially neutrophil elastase. Defects in SERPINA1 are the cause of alpha-1-antitrypsin deficiency (A1ATD).

Serpin A1 参考文献

Serpin A1上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Alfalastin (LFB SA) 批准上市 Lfb Biotechnologies Alfalastin France α1抗胰蛋白酶缺乏症 Lfb Biotechnologies 2005-08-01 α1抗胰蛋白酶缺乏症 详情

Serpin A1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
VX-864 VX-864 临床二期 Vertex Pharmaceuticals Incorporated α1抗胰蛋白酶缺乏症 详情
Alpha-1 antitrypsin (Kalytera Therapeutics) 临床阶段不明 Clalit Health Services 详情
Belcesiran DCR-A1AT 临床二期 Dicerna Pharmaceuticals α1抗胰蛋白酶缺乏症, 肝脏疾病 详情
ARO-AAT TAK-999; ARO-AAT 临床三期 Arrowhead Pharmaceuticals α1抗胰蛋白酶缺乏症 详情

消息提示

请输入您的联系方式,再点击提交!

确定